screenshot of video for Predicting ‘Long COVID’ At Initial Point of COVID-19 Diagnosis

Predicting ‘Long COVID’ At Initial Point of COVID-19 Diagnosis

Researchers have identified several factors that can be measured at the initial point of COVID-19 diagnosis that anticipate if a patient is likely to develop long COVID. They also found that mild cases of COVID-19, not just severe cases, are associated with long COVID. Their findings were published by the journal Cell.

Predicting ‘Long COVID’ At Initial Point of COVID-19 Diagnosis
Predicting ‘Long COVID’ At Initial Point of COVID-19 Diagnosis
screenshot of video for Research Roundtable with Dr. Jim Heath on COVID

Research Roundtable with Dr. Jim Heath on COVID

On January 18, 2022, Dr. Jim Heath gave a talk on COVID at the first Research Roundtable event of 2022. Research Roundtable is a series of ISB hosted conversations with our leading scientists on the latest research happening at ISB. Designed for a lay audience, this series is open to all. Attendees have the opportunity to ask questions directly to our scientists.

Research Roundtable with Dr. Jim Heath on COVID
Research Roundtable with Dr. Jim Heath on COVID
Drs. Jim Heath, Yapeng Su and Jihoon Lee

Metabolic Changes in Plasma and Immune Cells Associated with COVID-19 Severity, May Predict Patient Survival

Researchers from Institute for Systems Biology (ISB), Fred Hutchinson Cancer Research Center and other organizations have uncovered underlying metabolic changes that regulate how immune cells react to COVID-19. These findings are associated with COVID-19 severity and may predict patient survival. The work was published in the journal Nature Biotechnology.

Metabolic Changes in Plasma and Immune Cells Associated with COVID-19 Severity, May Predict Patient Survival
Metabolic Changes in Plasma and Immune Cells Associated with COVID-19 Severity, May Predict Patient Survival
Glioblastoma tumor slice and corresponding density map

Looking at Tumors Through a New Lens: New Research May Improve Efficacy of Glioblastoma Immunotherapy

To improve the efficacy of neoadjuvant immune checkpoint blockade against glioblastoma, researchers are looking for vulnerabilities in surgically removed tissues – a difficulty due to the vast differences within the tumor and between patients. To address this, ISB researchers and their collaborators developed a new way to study tumors.

Looking at Tumors Through a New Lens: New Research May Improve Efficacy of Glioblastoma Immunotherapy
Looking at Tumors Through a New Lens: New Research May Improve Efficacy of Glioblastoma Immunotherapy

ISB Undergraduate Researcher Daniel Chen Earns Goldwater Scholarship

Daniel Chen, an undergraduate researcher in ISB’s Heath Lab and junior at the University of Washington, has been awarded a prestigious Goldwater Scholarship. Chen has been a key member of ISB’s COVID-19 Immune Response Study.

ISB Undergraduate Researcher Daniel Chen Earns Goldwater Scholarship
ISB Undergraduate Researcher Daniel Chen Earns Goldwater Scholarship

Inside the intense world of COVID-19 science, and unexpected findings from Seattle researchers

GeekWire published a story spotlighting ISB’s COVID-19 research. Reporter Lisa Stiffler spoke with ISB President Dr. Jim Heath about the breakneck pace ISB and all of our collaborative partners are working at to tease out COVID’s biological secrets to advance the understanding and treatment of the novel coronavirus.

Inside the intense world of COVID-19 science, and unexpected findings from Seattle researchers
Inside the intense world of COVID-19 science, and unexpected findings from Seattle researchers
1 2 3 4 5